Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strom, T. B.
Right arrow Articles by Ruediger, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Strom, T. B.
Right arrow Articles by Ruediger, M.
J Am Soc Nephrol 15:1133-1139, 2004
© 2004 American Society of Nephrology

FRONTIERS IN NEPHROLOGY

Allogeneic Stem Cell–Derived "Repair Unit" Therapy and the Barriers to Clinical Deployment

Terry B. Strom*, Loren J. Field{dagger} and Manfred Ruediger{ddagger}

*Departments of Medicine and Surgery, Harvard Medical School, and Division of Immunology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; {dagger}Indiana University School of Medicine, Wells Center for Pediatric Research and Krannert Institute of Cardiology, Indianapolis; and {ddagger}Cardion AG, Max Planck Strasse 15a, D 40699 Erkrath, Germany.

Correspondence to Dr. Terry B. Strom, Departments of Medicine and Surgery, Harvard Medical School; Division of Immunology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, RN380, Boston, MA 02215. Phone: ; Fax: 617-632-0160; E-mail: tstrom{at}caregroup.harvard.edu

ABSTRACT. The development of cellular therapies has been seriously hampered by the paucity of cells available for grafting from living or cadaver donors. This sourcing problem can be resolved, at least in theory, by generating tissue-specific cells from autologous or allogeneic stem cells. Nonetheless, there are formidable barriers to the use of stem cells in the clinic. This review focuses on identifying and surmounting these barriers.




This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
B. M. Steenhard, K. S. Isom, P. Cazcarro, J. H. Dunmore, A. R. Godwin, P. L. St. John, and D. R. Abrahamson
Integration of Embryonic Stem Cells in Metanephric Kidney Organ Culture
J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1623 - 1631.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673